Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population

Francine Sirois1, Elias Gbeha, Ambaliou Sanni

  • 1Chronic Disease Program, Ottawa Health Research Institute, Ottawa Hospital, University of Ottawa, Ottawa, Canada.

Genetic Testing
|July 26, 2008
PubMed

Insights

The cardioprotective C679X mutation in the PCSK9 gene, linked to lower cholesterol and heart disease risk, is common in West Africa. Its varying frequency across ethnic groups may influence coronary heart disease incidence.

Area of Science:

  • Genetics
  • Cardiology
  • Population Health

Background:

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma cholesterol by affecting low-density lipoprotein receptor degradation.
  • Specific PCSK9 gene mutations, Y142X and C679X, are associated with lifelong hypocholesterolemia and reduced coronary heart disease (CHD) risk in African Americans.

Purpose of the Study:

  • To investigate the frequency of the cardioprotective PCSK9 Y142X and C679X mutations in West African populations.
  • To explore potential associations between mutation frequency and coronary heart disease incidence in the region.

Main Methods:

  • Genotyping of 520 individuals from Burkina-Faso, Benin, and Togo for PCSK9 mutations.
  • Analysis of mutation frequencies and heterozygosity rates across different ethnic groups.

Main Results:

  • The C679X mutation was detected in West African subjects, with an overall heterozygosity frequency of 3.3%.
  • The Y142X mutation was not detected.
  • Significant interethnic variations in C679X frequency were observed, ranging from 0% to 6.9%.

Conclusions:

  • The C679X mutation is prevalent in West Africa and may contribute to the lower incidence of coronary heart disease in the continent.
  • Observed frequency differences suggest potential roles of historical migration patterns and positive selection in shaping mutation distribution.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...